Medical/Pharmaceuticals
Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis
HANGZHOU, China, SHANGHAI and BOSTON, Oct. 28, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive long-term results from its pivotal Phase III clin...
2026-10-28 08:00
Fosun Health Makes Historic Debut at Canton Fair, Foshan Fosun Chancheng Hospital Showcases International Healthcare Services
GUANGZHOU, China, Oct. 28, 2026 /PRNewswire/ -- Fosun Health has become the first cross-border international healthcare group to exhibit at the Canton Fair in its 70-year history, debuting at the event's inaugural International Healthcare Zone alongside four Greater Bay Area (GBA) hospitals, incl...
2026-10-28 08:00
How to Care for Caregivers? NCCN Debuts Essential Guide for Supporting Loved Ones with Cancer
New, free book offers simple but empowering information on how to care for people with cancer while also caring for yourself. PLYMOUTH MEETING, Pa., Oct. 27, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States ...
2026-10-27 20:07
1395
Natus Celebrates Grand Opening of Suzhou Facility - Advancing Innovation in China, for China
Local development and manufacturing bring Natus neurodiagnostic expertise closer to clinicians and patients across China SUZHOU, China, Oct. 27, 2026 /PRNewswire/ -- Natus Medical Incorporated, the world's largest pure-play neurodiagnostic company, today celebrated the grand opening of its devel...
2026-10-27 11:13
2073
Asia-Pacific's First Whole-Body Clinical 5T MRI System Installed in Vietnam, Advancing a New Regional High-Field MRI Center of Excellence
HANOI, Vietnam, Oct. 27, 2026 /PRNewswire/ -- On October 26, 2026, United Imaging Healthcare's uMR Jupiter 5T MRI system was officially introduced at Hanoi Medical University Hospital (HMUH), marking the arrival ofthe first whole-body clinical 5T MRI in the Asia-Pacificregion (outside China). The...
2026-10-27 10:20
3662
Final OS Analysis Results of Phase III OptiTROP-Breast01 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in Annals of Oncology
CHENGDU, China, Oct. 26, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, the results of the final overall survival (OS) analysis o...
2026-10-26 18:33
2872
CityUHK researchers reveal how fructose can suppress liver cancer, opening a new therapeutic avenue
HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Fructose is an important nutrient, which despite having a chemical structure very similar to that of glucose, is metabolised very differently in the body. Research into fructose metabolism and its regulation of metabolism in the human body has in recent ye...
2026-10-26 17:50
2154
Tencent Cloud Enhances Telehealth Experiences for Care, Safeguarding Every Doctor-Patient Connection
HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Tencent Cloud, the cloud business of global technology company Tencent, today announced its collaboration with Care, one of Singapore's leading and most trusted telehealth digital solutions providers, to strengthen the quality and reliability of virtual he...
2026-10-26 16:57
1370
CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity
CS2009, an Innovative PD-1/VEGF/CTLA-4 trispecific antibody, demonstrates a differentiated profile through synergistic triple-pathway targeting, favorable tolerability and encouraging efficacy across multiple solid tumors Highlights * Three pillars of clinical validation: Clinical data from ov...
2026-10-26 16:45
1714
Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity
- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models. - ASC39 demonstrated eloralintide-like selectivity for human amylin 1 receptor (hAMY1R) over human calcitonin receptor (hCTR) (40-fold), support...
2026-10-26 08:10
5806
Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026
SHANGHAI and HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-10-26 08:00
2059
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
* Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of death (HR 0.69; 95% CI 0.54–0.89; one-sided P = 0.0021). * The 2-year OS rate was 54.1% vs 37.2%, an improvement of 16.9%; with a median follow-u...
2026-10-25 19:12
4358
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
* PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P<0.0001 ), and median PFS was 15.0 months (95% CI 9.9-NE) and 5.7 months (95% CI 5.5-7.4) in the two groups, respectively. * Responses were more dur...
2026-10-25 18:44
4983
Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026
BEIJING, Oct. 24, 2026 /PRNewswire/ -- Likang Life Sciences ("Likang"), a biotechnology company advancing AI-enabled personalized cancer immunotherapies, sponsored and exhibited at the Abu Dhabi Future Health Summit 2026, held from 20 to 22 October at ADNEC Centre Abu Dhabi. The summit marked a m...
2026-10-24 19:38
6948
Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented at 2026 ESMO
CHENGDU, China, Oct. 24, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress held in Madrid, updated results from the Phase II MK-2870-002/SKB264-II-06 ...
2026-10-24 18:15
7491
19th EU-China Business Meeting Concludes! Third-Generation Triple-Helix Biomimetic Collagen Medical Devices Make Their Global Debut, Highlights from the Event
CHENGDU, China, Oct. 24, 2026 /PRNewswire/ -- At the 19th EU-China Business Meeting, co-hosted by the China Chamber of International Commerce (CCOIC) and the European Union Chamber of Commerce in China (EUCCC) in Chengdu, LivingPHOENIX Regenerative Technology Development (Chengdu) Co., Ltd. (her...
2026-10-24 09:29
7815
Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
- At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month progression-free survival rate of 81.9% (n=33) in 1L ES-SCLC - Among patients with at least six-months follow-up (n=15) treated at...
2026-10-23 20:04
2786
Alebund Pharmaceuticals Announces Poster Presentation by Partner R1 Therapeutics of Global Phase IIb Multi-Regional Clinical Trial Design for AP306 at ASN Kidney Week 2026
SHANGHAI, Oct. 23, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that its partner, R1 Therapeutics, Inc. ("R1"), presented a trial-in-progress poster outlining the design of the ...
2026-10-23 19:00
3418
Carnyx Therapeutics Unveils Oral Sleep Candidate CNYX-005 with Preclinical Data Showing Increased NREM Sleep
Preclinical study shows 1.5- to 2-hour increase in total sleep time as Company
advances toward clinical development and attracts Chris Brearley, M.D., as
Chief Medical Officer
INDIANAPOLIS, Oct. 23, 2026 /PRNewswire/ -- Carnyx Therapeutics Ltd.
2026-10-23 08:30
2594
Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
- With first patient dosed in Phase III clinical trial, Ascletis' strategic partner Sagimet Biosciences Inc. ("Sagimet") advances denifanstat (ASC40)'s U.S. registrational program, building on positive Phase III clinical results in China from Ascletis - Pivotal trial designed to enroll approxima...
2026-10-23 08:10
3310
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 307 media titles]
2026-10-27 13:40
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 296 media titles]
2026-10-22 22:35
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 281 media titles]
2026-10-23 21:52
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 278 media titles]
2026-10-21 15:00
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
36572
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
35733
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
34483
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
28871
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
17778
